Immunome (IMNM) Stock Forecast & Price Target

Q: What analysts cover Immunome?

Immunome has been rated by research analysts at Barclays , Citigroup , HC Wainwright , Leerink Partners , Truist Financial , Wedbush , and Weiss Ratings in the past 90 days.

$22.83 +0.05 (+0.22%)

As of 11:12 AM Eastern

Compare

Immunome - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 14 Analyst Ratings

Sell
1

Hold
0

Buy
13

Based on 14 Wall Street analysts who have issued ratings for Immunome in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 14 analysts, 1 has given a sell rating, and 13 have given a buy rating for IMNM.

Consensus Price Target

$33.17
45.28% Upside

According to the 14 analysts' twelve-month price targets for Immunome, the average price target is $33.17. The highest price target for IMNM is $40.00, while the lowest price target for IMNM is $22.00. The average price target represents a forecasted upside of 45.28% from the current price of $22.83.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for IMNM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Immunome and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

IMNM Analyst Ratings Over Time

Type	Current Forecast 7/22/25 to 7/22/26	1 Month Ago 6/22/25 to 6/22/26	3 Months Ago 4/23/25 to 4/23/26	1 Year Ago 7/22/24 to 7/22/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	12 Buy rating(s)	10 Buy rating(s)	6 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$33.17	$33.17	$33.45	$23.33
Forecasted Upside	45.28% Upside	72.92% Upside	45.52% Upside	110.78% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

IMNM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IMNM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Immunome Stock vs. The Competition

Type	Immunome	Medical Companies	Broader Market
Consensus Rating Score	2.86	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	45.60% Upside	867.20% Upside	14.57% Upside
News Sentiment Rating	Neutral News See Recent IMNM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/21/2026	Wedbush 5 of 5 stars	David Nierengarten 5 of 5 stars	Reiterated Rating	Outperform	$31.00	+39.53%
7/17/2026	Weiss Ratings 5 of 5 stars		Reiterated Rating	Sell (D-)
7/9/2026	Citigroup 4 of 5 stars		Reiterated Rating	Buy
7/9/2026	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andres Y. Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy
5/28/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Supawat Thongthip Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$36.00 ➝ $37.00	+67.35%
5/28/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lukas Shumway Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Overweight	$36.00	+62.82%
5/15/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Berens Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$37.00 ➝ $33.00	+49.86%
3/4/2026	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Vogel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$33.00 ➝ $36.00	+59.86%
3/4/2026	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sudan Loganathan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$33.00 ➝ $30.00	+39.28%
12/16/2025	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chad Messer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$22.00 ➝ $32.00	+34.35%
BofA: Digital Dollar Coming 2025-2030 (Ad) A little-known meeting in 1910 cost the average American family their entire financial freedom. They met in secret, used fake names, and told absolutely no one where they were going. On November 22nd, 1910, seven of America's most powerful bankers gathered on Jekyll Island to design the Federal Reserve. Their goal? To create a system where they control the money supply and you foot the bill. That system has created $38 trillion in debt, destroyed 98% of the dollar's purchasing power, and now they're preparing the final move: Central bank digital currencies (CBDCs). But if you have at least $100,000 saved and you're concerned about what's coming, you need to hear this. Watch now before this presentation is taken down.
12/16/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Schmidt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$25.00 ➝ $35.00	+54.59%
12/16/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cory Kasimov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$18.00 ➝ $40.00	+75.43%
9/22/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy	$26.00	+176.89%
8/7/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Cheng Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$23.00 ➝ $22.00	+122.90%
3/11/2025	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Outperform	$20.00	+125.99%
11/14/2024	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Biren Amin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$23.00 ➝ $21.00	+81.19%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 11:12 AM ET.

IMNM Forecast - Frequently Asked Questions

According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Immunome is $33.17, with a high forecast of $40.00 and a low forecast of $22.00.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunome in the last year. There is currently 1 sell rating and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" IMNM shares.

According to analysts, Immunome's stock has a predicted upside of 45.28% based on their 12-month stock forecasts.

Over the previous 90 days, Immunome's stock had 1 upgrade by analysts.

Immunome has been rated by research analysts at Barclays, Citigroup, HC Wainwright, Leerink Partners, Truist Financial, Wedbush, and Weiss Ratings in the past 90 days.

Analysts like Immunome more than other "medical" companies. The consensus rating for Immunome is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how IMNM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Immunome Recommendations

This page (NASDAQ:IMNM) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunome (IMNM) Stock Forecast & Price Target